Comparative Analysis of Clinicopathological Features and Outcomes Between Kidney-Limited and Systemic Thrombotic Microangiopathy: A Study Based on a Semiquantitative Pathological Scoring System Authors: Yan Pan, Yongxin Zhao, Xi Li, Xueping Wu, Bowen Chen, Mengru Lu, Rubing Shen, WeiDong Chen, Lei Liu Published: 2026 ABSTRACT AbstractObjectiveTo systematically compare the clinicopathological features and prognostic outcomes of renal-limited thrombotic microangiopathy (RL-TMA) and systemic thrombotic microangiopathy (Sys-TMA) using a semiquantitative pathological scoring system.MethodsWe retrospectively analyzed 47 patients with biopsy-proven TMA between 2018 and 2025, categorized as RL-TMA (n = 42) or Sys-TMA (n = 5) based on systemic manifestations. Clinical, pathological, and follow-up data were collected. A composite renal endpoint served as the primary outcome. Kaplan–Meier and Cox regression analyses were used for survival analysis and prognostic factor identification.ResultsRL-TMA patients were older, with higher hemoglobin and platelet levels, lower lactate dehydrogenase, less complement C3 consumption, and significantly fewer multiorgan dysfunctions than Sys-TMA patients. Pathologically, Sys-TMA was dominated by acute microvascular lesions, whereas RL-TMA showed more chronic changes (glomerulosclerosis, arteriolar hyalinosis) and more frequent immune complex deposition. Total immunofluorescence intensity and IgG, IgG2, IgG4, and C1q deposition were significantly higher in RL-TMA (all P < 0.05). Over a median follow-up of 16–20 months, end-stage kidney disease incidence did not differ significantly between groups (9.5% vs 0%, P > 0.05). In RL-TMA, univariate analysis showed that lower hemoglobin was associated with worse renal outcomes (HR = 0.946, P = 0.004). Serum albumin showed no clear association (HR = 0.992, P = 0.862), while pathological scores lacked independent predictive value. Kaplan-Meier analysis showed no statistically significant difference in renal progression-free survival between the two groups (P = 0.97).ConclusionThis study delineates significant differences between RL-TMA and Sys-TMA across clinical, pathological, and prognostic dimensions, suggesting that RL-TMA may represent a distinct clinicopathological entity, warranting further validation in larger prospective studies. Given the small sample size of the Sys-TMA group, these results should be interpreted as exploratory and hypothesis-generating. Hemoglobin levels showed an association with renal outcomes in univariate analysis, but this finding requires further investigation in larger cohorts before any clinical utility can be established.Keywords: renal-limited thrombotic microangiopathy, RL-TMA, Thrombotic microangiopathy, clinical manifestations, pathological features, prognosis Introduction Thrombotic microangiopathy (TMA) comprises a heterogeneous group of disorders characterized by microvascular endothelial injury. Among these, complement-mediated TMA (C-TMA), resulting from dysregulation of the alternative complement pathway, is of particular clinical importance, typically presenting with systemic microangiopathic hemolytic anemia, thrombocytopenia, and multiorgan dysfunction. However, a distinct clinical subgroup has been recognized: patients who exhibit renal pathological findings that are characteristic of TMA—such as subendothelial edema, microthrombus formation, and glomerular basement membrane duplication—in the absence of corresponding systemic clinical manifestations.1–3 This entity is termed renal-limited thrombotic microangiopathy (RL-TMA). Current understanding of RL-TMA remains incomplete. It is debated whether RL-TMA represents an early or forme fruste stage of systemic thrombotic microangiopathy or constitutes a distinct clinicopathological subtype. Furthermore, the clinicopathological have not been fully elucidated. The importance of resolving this debate extends beyond mere classification, as it has direct implications for treatment decisions. If RL-TMA represents an early stage of systemic TMA, patients might benefit from early complement inhibition; conversely, if it constitutes a distinct entity, treatment should be tailored accordingly to avoid unnecessary immunosuppression. However, direct comparisons between RL-TMA and Sys-TMA using standardized pathological scoring systems are notably lacking. The present study was therefore designed to address this gap. Recently, Chen et al4 developed and validated a semiquantitative pathological scoring system for renal TMA, providing a robust and objective tool for comparing pathological patterns across different TMA subtypes. Building upon this framework, the present study aimed to apply the aforementioned pathological scoring system to systematically compare the clinicopathological characteristics and prognostic outcomes between strictly defined renal-limited thrombotic microangiopathy (RL-TMA) and systemic thrombotic microangiopathy (Sys-TMA). The specific objectives were as follows: (1) to compare baseline clinical characteristics and renal pathological patterns between the two entities; and (2) to investigate long-term renal outcomes and associated risk factors in patients with RL-TMA. The findings of this study are expected to enhance the understanding of the TMA disease spectrum and to provide evidence for risk stratification and individualized management of RL-TMA. Materials and Methods Study Design and Patient Cohort This retrospective cohort study consecutively enrolled patients diagnosed with thrombotic microangiopathy (TMA) by renal biopsy at our center between April 2018 and August 2025. Pathological Diagnostic Criteria for Renal TMA The pathological diagnosis of renal TMA was established according to predefined morphological criteria.4 Renal biopsy specimens were considered diagnostic of TMA if at least one of the following features was present: (1) thrombus formation in arterioles and/or arteries; (2) glomerular thrombus formation; (3) onion-skin-like changes of arterioles and/or arteries; (4) myxoid (mucoid) edema of arterioles and/or arteries; and (5) subendothelial edema of glomerular capillaries observed by electron microscopy. Patient Stratification Patients were stratified into two groups based on the presence of systemic manifestations: Renal-limited thrombotic microangiopathy (RL-TMA) Group: Patients met the pathological diagnostic criteria but lacked the typical systemic thrombotic microangiopathy triad. Specifically, RL-TMA was defined by a persistently normal platelet count (>120 × 109/L) and the absence of significant microangiopathic hemolytic anemia, evidenced by a peripheral blood schistocyte proportion <1% and normal or only mildly elevated lactate dehydrogenase (LDH) levels. Systemic thrombotic microangiopathy Group (Sys-TMA): Patients met the pathological diagnostic criteria and exhibited typical laboratory evidence of thrombocytopenia (platelet count <120 × 109/L) and/or microangiopathic hemolytic anemia, defined by an increased proportion of peripheral blood schistocytes and/or LDH levels exceeding 1.5 times the upper limit of normal. Diagnostic Work-Up and Exclusion of Other TMA Subtypes To ensure accurate classification, all patients underwent systematic evaluation to exclude other TMA subtypes. ADAMTS13 activity testing was performed in patients with clinically suspected TTP, and stool cultures/serological testing for STEC was performed in those with diarrhea or suspected enteric infection. Comprehensive evaluation for secondary causes (autoimmune diseases, infections, drug-related factors, and malignancy) was conducted in all patients. Complement-related work-up, including complement factor levels (CFH, CFI, MCP) and functional assays, was performed in patients with suspected complement-mediated TMA. Complement genetic analysis was recommended for patients with early-onset disease, family history of TMA, recurrent episodes, or without identifiable secondary triggers. However, due to the retrospective design and variability in outside-hospital work-ups, not all patients received complete complement genetic testing; this limitation is addressed in the Discussion section. Data Collection Clinical Data Baseline characteristics and follow-up data were collected for all patients. Baseline Data: Included demographics (age, sex, body mass index), blood pressure, and laboratory parameters (serum creatinine, estimated glomerular filtration rate, 24-hour urinary protein excretion, serum albumin, hemoglobin, platelet count, lactate dehydrogenase, and complement C3 and C4 levels). Baseline extrarenal organ involvement was defined as follows: renal—acute kidney injury per KDIGO serum creatinine criteria; gastrointestinal—presence of diarrhea, gastrointestinal bleeding, or abdominal pain; central nervous system—occurrence of seizures, altered consciousness, stroke, or confusion. Follow-up Data: At each visit, serum creatinine, estimated glomerular filtration rate, serum albumin, lactate dehydrogenase, C-reactive protein, complete blood count, quantitative urinary protein excretion, and urinary red blood cell counts were recorded. Renal Pathological Evaluation All renal biopsy specimens were evaluated by light microscopy, direct immunofluorescence, and electron microscopy. The semiquantitative pathological scoring system for renal complement-mediated TMA developed by Chen et al4 was applied. Two renal pathologists independently scored 15 parameters encompassing glomerular microangiopathic lesions, vascular microangiopathic lesions, and chronic tubulointerstitial changes (detailed in Table S1). Discrepancies were resolved by consensus. Treatment and Follow-Up Treatment: Management was individualized per clinical condition and guidelines, including supportive therapy with renin–angiotensin–aldosterone system inhibitors, immunomodulatory agents (glucocorticoids and other immunosuppressants), plasma therapy (plasma exchange or infusion), and targeted complement inhibition with eculizumab. Follow-up Schedule: Patients underwent scheduled outpatient follow-up at 1, 3, 6, and 12 months after treatment initiation, and subsequently at 6- to 12-month intervals. Key clinical parameters (renal function, proteinuria) and predefined endpoint events were recorded at each visit. Outcome Definitions and Assessment Endpoints were stratified based on baseline renal function: For patients on dialysis at baseline: The primary efficacy endpoint was dialysis independence, defined as successful discontinuation of dialysis for at least 30 days with stable renal function post-intervention. For patients not on dialysis at baseline: The primary efficacy endpoint was renal functional response, a composite endpoint requiring both: (1) at 6 months post-treatment, a serum creatinine increase of <30% from baseline or an estimated glomerular filtration rate decline of <30%; and (2) no initiation of long-term renal replacement therapy during follow-up. Composite Renal Endpoint (for all patients): Defined as progression to end-stage kidney disease (ESKD) requiring long-term renal replacement therapy or kidney transplantation, or all-cause mortality. Statistical Analysis Statistical analyses were performed using SPSS software (version 26.0). Normally distributed continuous variables are presented as mean ± standard deviation and compared using the independent-samples *t*-test. Non-normally distributed continuous variables are presented as median (interquartile range) and compared using the Mann–Whitney U-test. Categorical variables are expressed as counts (percentages) and compared using the χ2-test or Fisher’s exact test, as appropriate. Survival curves were constructed using the Kaplan–Meier method and compared with the Log rank test. Univariate Cox proportional hazards regression was performed to identify potential prognostic factors. As an exploratory retrospective cohort study with a limited number of outcome events (n=4), multivariate Cox regression was not performed due to model non-convergence. All reported results are based on univariate analyses and should be interpreted as exploratory. All tests were two-sided, with P < 0.05 considered statistically significant. As an exploratory retrospective cohort study, no a priori sample size calculation was performed. Given the exploratory nature of this study and the primary objective of hypothesis generation, no adjustment for multiple comparisons (eg, Bonferroni correction) was applied, as such adjustment would increase the risk of type II errors and potentially obscure meaningful signals. Results Baseline Clinicopathological Characteristics and Etiology of RL-TMA versus Sys-TMA Compared with patients with systemic thrombotic microangiopathy (Sys-TMA), those with renal-limited thrombotic microangiopathy (RL-TMA) were significantly older at diagnosis (mean age: 46.69 vs 31.60 years, p = 0.032). RL-TMA patients had higher hemoglobin levels (116.76 g/L vs 89.00 g/L, p = 0.038) and platelet counts (242.68 × 109/L vs 75.40 × 109/L, p < 0.001), but significantly lower lactate dehydrogenase levels (302.82 U/L vs 579.33 U/L, p = 0.023). With respect to complement profiles, Sys-TMA patients exhibited more pronounced complement consumption, with significantly lower serum C3 levels compared with RL-TMA patients (0.57 g/L vs 0.93 g/L, p = 0.008). Regarding renal involvement, the RL-TMA group showed a markedly lower urinary red blood cell count (32.40/μL vs 482.50/μL, p = 0.002). Notably, the incidence of multiorgan dysfunction was substantially lower in RL-TMA patients (4.8% vs 80.0%, P < 0.001), with the majority (73.8%) showing no evidence of organ dysfunction at diagnosis. See Table 1. Table 1Comparison of Baseline Clinical Characteristics Between Patients with RL-TMA and Sys-TMAVariablesRenal-Limited TMA (N = 42)Systemic TMA (N = 5)pDemographic Characteristics Age (years) Mean ± SD46.69 ±14.0131.60 ±18.150.032 Body Mass Index (kg/m2) Mean ± SD27.55 ±4.7523.63 ±4.680.089 Systolic Blood Pressure (mmHg) Mean ± SD157.26 ±26.84156.20 ±16.100.932 Diastolic Blood Pressure (mmHg) Mean ± SD99.14 ±23.80101.40 ±21.960.841 Sex0.991 Male n (%)30 (71.4)3 (60.0) Female n (%)12 (28.6)2 (40.0)Standard Laboratory Tests White Blood Cell Count (×109/L) Mean ± SD7.17 ±1.868.31 ±4.080.269 Hemoglobin (g/L) Mean ± SD116.76 ±26.5089.00 ±36.170.038 Platelet Count (×109/L) Mean ± SD242.68 ±91.5875.40 ±35.06<0.001 Serum Creatinine (μmol/L) Mean ± SD273.98 ±287.88288.60 ±382.260.918 Estimated Glomerular Filtration Rate (mL/min/1.73 m2) Mean ± SD62.35 ±34.6272.68 ±47.500.547 Serum Albumin (g/L) Mean ± SD35.28 ±7.7729.06 ±4.130.087 Lactate Dehydrogenase (U/L) Mean ± SD302.82 ±137.92579.33 ±365.620.023 Alkaline Phosphatase (U/L) Mean ± SD86.83 ±61.9758.25 ±16.640.367 C-reactive Protein (mg/L) Mean ± SD12.74 ±26.2621.29 ±35.510.550 24-hour Urinary Protein (g/24 h) Mean ± SD3.19 ±2.262.77 ±0.840.719 Urinary RBC Count (cells/μL) Mean ± SD32.40 ±67.04482.50 ±855.140.002 Complement C3 (g/L) Mean ± SD0.93 ±0.250.57 ±0.380.008 Complement C4 (g/L) Mean ± SD0.28 ±0.120.19 ±0.160.101Organ dysfunction, n (%)<0.001 Hepatic involvement, n (%)1 (2.4)0 (0.0) Central nervous system involvement, n (%)1 (2.4)0 (0.0) Retinal involvement, n (%)2 (4.8)0 (0.0) Cardiac involvement, n (%)3 (7.1)0 (0.0) Hematologic involvement, n (%)0 (0.0)1 (20.0) Fundus involvement, n (%)2 (4.8)0 (0.0) Multiple organ involvement, n (%)2 (4.8)4 (80.0) None, n (%)31 (73.8)0 (0.0) Comparison of Baseline Clinical Characteristics Between Patients with RL-TMA and Sys-TMA In the RL-TMA group, the underlying renal diagnoses were systematically reviewed based on pathological reports. The most common diagnoses included hypertension (22 cases, 52.4%), malignant hypertension (6 cases, 14.3%), IgA nephropathy (3 cases, 7.1%), diabetic nephropathy (5 cases, 11.9%), membranous nephropathy (4 cases, 9.5%), lupus nephritis (4 cases, 9.5%), other defined causes (5 cases, 11.9%), and unidentified or unclassified causes (5 cases, 11.9%). Notably, immune complex-mediated glomerular diseases (IgA nephropathy, membranous nephropathy, and lupus nephritis) collectively accounted for 40.5% (17/42) of RL-TMA cases. In terms of etiological distribution, the proportion of patients with hypertension (including malignant hypertension) was significantly higher in the RL-TMA group than in the Sys-TMA group (52.4% vs 0%, P = 0.002). Other etiologies, such as systemic lupus erythematosus and pregnancy-associated hemolytic uremic syndrome, showed numerical differences between the two groups; however, due to the small sample size, these differences did not reach statistical significance (all P > 0.05) (Table 2). Table 2Comparison of Etiological Factors Between RL-TMA and Sys-TMAEtiological FactorsRL-TMA (n = 42)Sys-TMA (n = 5)P value*Malignant hypertension6 (14.3)1 (20.0)0.999Hypertension22 (52.4)0 (0.0)0.002Diabetes mellitus5 (11.9)0 (0.0)0.999Obesity6 (14.3)0 (0.0)0.999Anti-VEGF therapy1 (2.4)0 (0.0)0.999Post-HSCT0 (0.0)1 (20.0)0.106Systemic lupus erythematosus4 (9.5)2 (40.0)0.116Pregnancy-associated HUS0 (0.0)1 (20.0)0.106IgA nephropathy3 (7.1)0 (0.0)0.999Hematologic malignancy1 (2.4)0 (0.0)0.999Genetic factors1 (2.4)0 (0.0)0.999Idiopathic5 (11.9)1 (20.0)0.538Number of etiologiesSingle etiology32 (76.2)4 (80.0)0.999Two or more etiologies10 (23.8)1 (20.0)0.999Notes: *P values were calculated using Fisher’s exact test. Multivariate analysis was not performed due to the small sample size of the Sys-TMA group and sparse cell counts in some etiological categories. Comparison of Etiological Factors Between RL-TMA and Sys-TMA Notes: *P values were calculated using Fisher’s exact test. Multivariate analysis was not performed due to the small sample size of the Sys-TMA group and sparse cell counts in some etiological categories. The Sys-TMA group was characterized predominantly by acute active lesions, showing more severe glomerular endothelial cell swelling and proliferation (1.20 ± 1.10 vs 0.48 ± 0.51, P = 0.012), as well as more pronounced acute vascular microangiopathy (2.40 ± 2.07 vs 1.14 ± 1.03, P = 0.026). These vascular changes were mainly manifested by endothelial swelling and subintimal myxoid edema (P = 0.036). In contrast, the RL-TMA group exhibited more chronic changes accompanied by prominent immune complex deposition. Scores for chronic glomerular microangiopathy (1.83 ± 0.91 vs 1.00 ± 1.22, P = 0.068) and arteriolar hyalinosis (1.38 ± 1.06 vs 0.20 ± 0.45, P = 0.018) were higher in the RL-TMA group. Additionally, RL-TMA patients had significantly higher total immunofluorescence intensity and stronger specific deposition of IgG, IgG2, IgG4, and C1q (all P < 0.05). See Table 3. Table 3Comparison of Renal Pathological Features Between RL-TMA and Sys-TMAVariableRenal-Limited TMA (n = 42)Systemic TMA (n = 5)pGlomerular microangiopathy:Acute glomerular microangiopathyMean ± SD1.10 ±1.212.20 ±1.920.076Glomerular endothelial swelling and proliferation Mean ± SD0.48 ±0.511.20 ±1.100.012Subendothelial widening (electron microscopy) Mean ± SD0.29 ±0.460.20 ±0.450.693Mesangiolysis Mean ± SD0.10 ±0.300.00 ±0.000.481Glomerular thrombosis Mean ± SD0.24 ±0.660.80 ±1.100.099Chronic glomerular microangiopathy Mean ± SD1.83 ±0.911.00 ±1.220.068Global and segmental glomerulosclerosis (including ischemic glomerulosclerosis) Mean ± SD1.83 ±0.911.00 ±1.220.068Vascular microangiopathy:Acute vascular microangiopathy Mean ± SD1.14 ±1.032.40 ±2.070.026Endothelial swelling and subintimal myxoid edema Mean ± SD0.90 ±0.621.60 ±1.140.036Arteriolar/arterial fibrinoid necrosis or thrombosis Mean ± SD0.24 ±0.660.80 ±1.100.099Chronic vascular microangiopathy Mean ± SD3.07 ±1.941.20 ±1.640.045Onion-skin lesion Mean ± SD0.21 ±0.520.20 ±0.450.953Intimal fibrosis Mean ± SD1.51 ±1.000.80 ±0.840.136Arteriolar hyalinosis Mean ± SD1.38 ±1.060.20 ±0.450.018Chronic tubulointerstitial injury Mean ± SD3.76 ±1.853.20 ±1.790.522Tubular atrophy Mean ± SD1.76 ±0.941.40 ±0.890.427Interstitial fibrosis Mean ± SD2.10 ±0.971.80 ±1.100.526Total immunofluorescence intensity score10.60 ±10.292.90 ±4.360.003IgG Mean ± SD1.60 ±1.520.56 ±1.000.044IgG2 Mean ± SD1.40 ±1.670.13 ±0.520.001IgG3 Mean ± SD0.40 ±0.890.10 ±0.500.263IgG4 Mean ± SD1.20 ±1.300.26 ±0.790.027IgA Mean ± SD1.40 ±1.520.78 ±1.270.319IgM Mean ± SD0.40 ±0.890.15 ±0.480.317C3 Mean ± SD1.80 ±1.300.78 ±1.150.072C1q Mean ± SD1.20 ±1.640.17 ±0.590.006 Comparison of Renal Pathological Features Between RL-TMA and Sys-TMA Comparison of Baseline Clinical Characteristics, Etiologies, and Renal Pathological Features Between Dialysis and Non-Dialysis Patients in the RL-TMA Group To identify risk factors associated with rapid disease progression in patients with RL-TMA, we stratified the cohort into two subgroups according to whether dialysis was required at baseline and performed comparative analyses. There were no significant differences between the two groups in baseline demographic characteristics, including age, sex, body mass index (BMI), or blood pressure. However, patients in the dialysis group had significantly higher serum creatinine levels (897.60 ± 245.94 vs 189.70 ± 162.33 μmol/L, P < 0.001), markedly lower estimated glomerular filtration rate (eGFR) (13.64 ± 3.40 vs 68.94 ± 31.46 mL/min/1.73 m2, P < 0.001), higher C-reactive protein (CRP) levels (44.45 ± 67.62 vs 8.21 ± 9.18 mg/L, P = 0.003), and lower hemoglobin levels (88.60 ± 25.62 vs 120.57 ± 24.54 g/L, P = 0.010). Pathological analyses revealed that patients in the dialysis group exhibited significantly more severe chronic glomerular microangiopathy (2.60 ± 0.55 vs 1.73 ± 0.90, P = 0.043) and greater degrees of tubular atrophy (2.60 ± 0.89 vs 1.64 ± 0.90, P = 0.031) compared with those in the non-dialysis group. In addition, the proportion of patients with organ dysfunction was significantly higher in the dialysis group (P = 0.042). See Table 4. Table 4Clinicopathological Characteristics of RL-TMA Patients Stratified by Dialysis Requirement at BaselineVariableNon-Dialysis Group (N = 37)Dialysis Group (N = 5)pDemographic characteristics Age (years) Mean ± SD45.73 (14.23)53.80 (10.80)0.231 Body mass index (BMI, kg/m2) Mean ± SD27.79 (4.96)25.93 (2.67)0.420 Systolic blood pressure (mmHg) Mean ± SD156.70 (28.20)161.40 (14.28)0.718 Diastolic blood pressure (mmHg) Mean ± SD99.24 (24.96)98.40 (13.97)0.942 Sex0.327 Male, n (%)25 (67.6)5 (100.0) Female, n (%)12 (32.4)0 (0.0)Standard laboratory tests White blood cell count (WBC, ×109/L) Mean ± SD7.11 (1.91)7.62 (1.47)0.568 Hemoglobin (Hb, g/L) Mean ± SD120.57 (24.54)88.60 (25.62)0.010 Platelet count (PLT, ×109/L) Mean ± SD246.89 (95.03)212.40 (59.53)0.437 Serum creatinine (μmol/L) Mean ± SD189.70 (162.33)897.60 (245.94)<0.001 Estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) Mean ± SD68.94 (31.46)13.64 (3.40)<0.001 Serum albumin (ALB, g/L) Mean ± SD35.81 (7.73)31.34 (7.69)0.232 Lactate dehydrogenase (LDH, U/L) Mean ± SD287.42 (139.09)339.80 (143.05)0.493 Alkaline phosphatase (ALP, U/L) Mean ± SD86.73 (65.62)87.60 (24.85)0.977 C-reactive protein (CRP, mg/L) Mean ± SD8.21 (9.18)44.45 (67.62)0.003 24-hour urinary protein (UTP, g/24 h) Mean ± SD3.23 (2.34)2.80 (1.49)0.722 Urinary red blood cell count (RBCs, cells/μL) Mean ± SD32.68 (69.35)30.25 (53.18)0.947 Complement C3 (g/L) Mean ± SD0.95 (0.27)0.83 (0.10)0.411 Complement C4 (g/L) Mean ± SD0.28 (0.12)0.31 (0.08)0.597Organ involvement0.042 Liver involvement n (%)1 (2.7)0 (0.0) Multiple organ involvement n (%)2 (5.4)0 (0.0) Central nervous system involvement n (%)0 (0.0)1 (20.0) Retinal involvement n (%)2 (5.4)0 (0.0) Cardiac involvement n (%)2 (5.4)1 (20.0) Fundus involvement n (%)1 (2.7)1 (20.0) None n (%)29 (78.4)2 (40.0)Glomerular microangiopathy:Acute glomerular microangiopathy Mean ± SD1.22 (1.23)0.20 (0.45)0.077 Glomerular endothelial cell swelling and proliferation Mean ± SD0.51 (0.51)0.20 (0.45)0.197 Subendothelial edema of glomerular capillaries on electron microscopy Mean ± SD0.32 (0.47)0.00 (0.00)0.138 Mesangiolysis Mean ± SD0.11 (0.31)0.00 (0.00)0.452 Glomerular thrombosis Mean ± SD0.27 (0.69)0.00 (0.00)0.394Chronic glomerular microangiopathy Mean ± SD1.73 (0.90)2.60 (0.55)0.043 Global and segmental glomerulosclerosis (including ischemic sclerotic glomeruli) Mean ± SD1.73 (0.90)2.60 (0.55)0.043Vascular microangiopathy:Acute vascular microangiopathy Mean ± SD1.16 (1.09)1.00 (0.00)0.745 Vascular endothelial cell swelling and subintimal myxoid edema Mean ± SD0.89 (0.66)1.00 (0.00)0.718 Arteriolar/arterial fibrinoid necrosis and/or thrombosis Mean ± SD0.27 (0.69)0.00 (0.00)0.394Chronic vascular microangiopathy Mean ± SD2.97 (1.96)3.80 (1.79)0.378 Onion-skin lesions Mean ± SD0.19 (0.52)0.40 (0.55)0.401 Intimal fibrosis Mean ± SD1.44 (1.03)2.00 (0.71)0.251 Arteriolar hyalinosis Mean ± SD1.38 (1.09)1.40 (0.89)0.966Chronic tubulointerstitial lesions Mean ± SD3.57 (1.83)5.20 (1.30)0.063 Tubular atrophy Mean ± SD1.64 (0.90)2.60 (0.89)0.031 Interstitial fibrosis Mean ± SD2.03 (1.00)2.60 (0.55)0.221Immunofluorescence (IF) Mean ± SD2.86 (4.44)3.20 (4.09)0.874 IgG Mean ± SD0.53 (0.97)0.80 (1.30)0.575 IgG2 Mean ± SD0.15 (0.56)0.00 (0.00)0.563 IgG3 Mean ± SD0.12 (0.54)0.00 (0.00)0.631 IgG4 Mean ± SD0.21 (0.70)0.60 (1.34)0.316 IgA Mean ± SD0.81 (1.28)0.60 (1.34)0.740 IgM Mean ± SD0.17 (0.51)0.00 (0.00)0.472 C3 Mean ± SD0.72 (1.09)1.20 (1.64)0.391 C1q Mean ± SD0.19 (0.62)0.00 (0.00)0.495 Clinicopathological Characteristics of RL-TMA Patients Stratified by Dialysis Requirement at Baseline Association Between Clinicopathological Characteristics and Renal Prognosis in RL-TMA On univariate analysis, higher hemoglobin levels were linked to a lower risk of reaching the composite renal endpoint (HR = 0.946, 95% CI: 0.911–0.982, P = 0.004). In addition, higher baseline serum creatinine (HR = 1.006, 95% CI: 1.002–1.009, P = 0.003) and serum sodium (HR = 1.413, 95% CI: 1.021–1.954, P = 0.037) were also associated with an increased risk of the endpoint. Serum albumin, however, did not show a significant association (HR = 0.992, 95% CI: 0.901–1.091, P = 0.862). The multivariable model failed to converge due to the limited number of outcome events, precluding further assessment. See Table 5. Table 5Association Between Clinical and Pathological Characteristics of Renal-Limited TMA and Renal PrognosisTermUnivariate AnalysisHRCIPvalueWBC1.153(0.754, 1.763)0.511Hb0.946(0.911, 0.982)0.004PLT1.005(0.996, 1.014)0.292Serum creatinine1.006(1.002, 1.009)0.003eGFR0.806(0.631, 1.029)0.083NA+1.413(1.021 1.954)0.037ALB0.992(0.901, 1.091)0.862LDH0.999(0.992, 1.005)0.729CRP0.996(0.953, 1.041)0.862UTP1.073(0.759, 1.516)0.690Urinary red blood cell count (urine RBC count)1.005(0.999, 1.011)0.127Note: Multivariate analysis was not performed because only 4 patients reached the endpoint. Association Between Clinical and Pathological Characteristics of Renal-Limited TMA and Renal Prognosis Note: Multivariate analysis was not performed because only 4 patients reached the endpoint. Treatment and Outcome Assessment of Patients with RL-TMA and Sys-TMA In terms of treatment, patients in the systemic thrombotic microangiopathy (Sys-TMA) group more frequently received plasma exchange/infusion and eculizumab therapy (both 20.0%) than those in the RL-TMA group (0% and 2.4%, respectively); however, these differences did not reach statistical significance (P = 0.197 and P = 0.501, respectively). There were no significant differences between the two groups in the use of other treatments, including glucocorticoids and immunosuppressive agents. Among patients requiring dialysis at baseline, the proportion of patients who were able to discontinue dialysis was numerically higher in the Sys-TMA group (2/2, 100%) than in the RL-TMA group (1/5, 20.0%), although the difference was not statistically significant (P = 0.277). During long-term follow-up, four RL-TMA patients (9.5%) progressed to end-stage renal disease, whereas no such events occurred in the Sys-TMA group (P > 0.999). The duration of follow-up was comparable between the two groups. See Table 6. Table 6Comparison of Treatment Strategies and Follow-Up OutcomesVariablesRenal-Limited TMA (n = 42)Systemic TMA (n = 5)pTreatment modalities, n (%)Plasma exchange and/or plasma infusion (PE/PI)0 (0%)1 (20.0)0.197Glucocorticoids26 (61.9)4 (80.0)0.761Immunosuppressive agents0.663 Cyclophosphamide4 (9.5%)1 (20.0) Mycophenolate mofetil1 (2.4)1 (20.0) Tacrolimus1 (2.4)1 (20.0)Renin–angiotensin system inhibitors (RASi) ± SGLT2 inhibitors (eg, dapagliflozin)28 (66.7)3 (60.0)>0.999Eculizumab1 (2.4)1 (20.0)0.501Follow-up outcomesFollow-up duration (months), median (range)16.43 ±18.7220.00 ± 20.140.700On dialysis at baseline5 (11.9)2 (40.0)0.316Discontinuation of dialysis during follow-up among patients on dialysis at baseline1 (20.0)2 (100.0)0.277Death00End-stage renal disease (ESRD)4 (9.5)0>0.999Note: Percentages for immunosuppressive agents are based on the total number of patients in each group. Comparison of Treatment Strategies and Follow-Up Outcomes Note: Percentages for immunosuppressive agents are based on the total number of patients in each group. This figure shows the progression-free survival (PFS) curves for the two groups of patients. The y-axis represents the probability of surviving without reaching the endpoint event (defined as eGFR < 15 mL/min/1.73m2 or initiation of dialysis), while the x-axis represents the follow-up time (0–60 months). The blue curve represents the Sys-TMA group, and the red curve represents the RL-TMA group. Renal progression-free survival (PFS) curves (endpoint: eGFR <15 mL/min/1.73 m2 or dialysis initiation) are shown in Figure 1. The Sys-TMA group (blue curve) showed a steeper early decline (0–12 months), followed by a plateau. In contrast, the RL-TMA group (red curve) demonstrated a slower, continuous decline throughout follow-up, leading to an intersection of the curves later on. Log rank testing indicated no significant overall difference in PFS between the two groups (P = 0.97). See Figure 1. Kaplan–Meier Survival Curves of Renal Outcomes in Patients with RL-TMA and Sys-TMA. In univariate analyses, no significant associations were found between any glomerular or vascular microangiopathy parameters and renal outcomes. Consequently, the pathological lesions assessed in this study did not demonstrate predictive value for renal prognosis. See Table 7. Table 7Univariate Cox Regression Analysis of Pathological Parameters for Renal PrognosisTermUnivariate AnalysisHRCIP_valueAcute glomerular microangiopathy0.47(0.16–1.40)0.174Chronic glomerular microangiopathy1.71(0.72–4.06)0.222Acute vascular microangiopathy0.82(0.42–1.62)0.572Chronic vascular microangiopathy0.94(0.63–1.42)0.782Notes: Univariate Cox regression analysis was performed for each pathological parameter. Multivariate analysis was not performed due to the limited number of outcome events (n=4). Univariate Cox Regression Analysis of Pathological Parameters for Renal Prognosis Notes: Univariate Cox regression analysis was performed for each pathological parameter. Multivariate analysis was not performed due to the limited number of outcome events (n=4). Discussion Thrombotic microangiopathy (TMA) encompasses a spectrum of highly heterogeneous disorders. While complement-mediated TMA (C-TMA) has drawn significant clinical and research focus due to its systemic manifestations and targeted treatment options, a distinct subgroup of patients presents with typical renal TMA pathology in the absence of systemic hematologic abnormalities, termed renal-limited thrombotic microangiopathy (RL-TMA). Applying a validated semiquantitative pathological scoring system, this study provides the first systematic comparison between RL-TMA and systemic thrombotic microangiopathy (Sys-TMA) within a rigorously defined C-TMA cohort. Our findings reveal substantial differences between the two entities regarding baseline clinical profiles, etiological spectra, patterns of renal pathological injury, and clinical trajectories. Taken together, these results provide preliminary evidence suggesting that RL-TMA may constitute a distinct clinicopathological phenotype, which requires confirmation in larger cohorts with a unique clinicopathological phenotype. Clinical and Pathological Distinctions Between RL-TMA and Sys-TMA Suggest a Spectrum of Disease Severity This study reveals distinct clinical presentations between renal-limited thrombotic microangiopathy (RL-TMA) and systemic thrombotic microangiopathy (Sys-TMA). RL-TMA patients present at an older age, with less pronounced elevation of lactate dehydrogenase (LDH), minimal complement C3 consumption, and rare involvement of extra-renal organs. These features align closely with observations from the large French MATRIX cohort, which similarly reported that patients with renal-limited thrombotic microangiopathy (RL-TMA) exhibit milder hematologic abnormalities, lower rates of C3 consumption, and significantly lower incidences of severe illness and in-hospital mortality compared to those with systemic thrombotic microangiopathy.5 The study by Cavero et al further supports these findings, demonstrating that patients with typical TMA hematologic features tend to be younger, have a higher prevalence of pathogenic complement variants, and carry a greater risk of progression to kidney failure.6 Collectively, this body of evidence suggests that RL-TMA may not merely represent a clinical subtype of systemic thrombotic microangiopathy, but rather a distinct clinicopathological entity. Its relatively favorable prognosis may be attributable to an overall lower intensity of complement activation. This concept is consistent with the hypothesis proposed by Noris et al,7 which posits that in a subset of patients with complement-mediated TMA (C-TMA), complement activation may remain localized and of insufficient magnitude to trigger systemic microangiopathic hemolysis and thrombocytopenia, yet still be adequate to induce focal endothelial injury and pathological changes in specific target organs, such as the kidney. Differences in Etiologic Spectrum Between RL-TMA and Sys-TMA and Their Diagnostic Implications Our etiologic analysis suggests that RL-TMA and systemic thrombotic microangiopathy (Sys-TMA) may arise from distinct underlying causes. Hypertension (including malignant hypertension) was present in 66.7% of RL-TMA patients, consistent with the notion that chronic endothelial injury plays a key role in this condition, whereas autoimmune diseases (eg, systemic lupus erythematosus), post-hematopoietic stem cell transplantation status, and pregnancy-associated hemolytic uremic syndrome were more commonly associated with Sys-TMA. This differential distribution points toward divergent pathogenic mechanisms. RL-TMA may be more closely linked to chronic endothelial injury, such as that induced by long-standing hypertension,6,8 which typically progresses gradually and may not trigger robust systemic complement activation. In contrast, Sys-TMA appears more frequently related to triggers capable of inducing acute and widespread complement activation, including autoimmune disorders, pregnancy, and transplantation9–12 —conditions often accompanied by overt complement pathway abnormalities. This finding carries significant implications for clinical differential diagnosis. Notably, hypertension-associated renal microvascular disease—particularly malignant hypertension—and complement-mediated atypical hemolytic uremic syndrome (aHUS) exhibit highly similar pathological features and often present with severe hypertension, making clinical distinction challenging.13 In practice, the differential diagnosis in such cases should extend beyond primary aHUS to include drug-related malignant hypertension, specific systemic diseases (eg, scleroderma renal crisis), and IgA nephropathy, all of which can be complicated by TMA.6,14 The key to differentiation lies in identifying underlying complement abnormalities, as patients with complement gene mutations or functional defects often exhibit more severe pathological injury, higher relapse rates, and poorer outcomes—even when blood pressure is adequately controlled.15 In this study, most cases did not undergo systematic complement testing (eg, C5b-9, complement factor assays, genetic sequencing) in the early stages, and the sample size of the Sys-TMA group was limited. These factors contributed to the inability to identify independent etiologic risk factors in the multivariate analysis. Nevertheless, the observed distribution trends align with extensive clinical experience and the aforementioned literature evidence. Based on these findings, we recommend systematic complement-related testing for all patients with TMA, irrespective of whether their presentation appears “renal-limited”.16 This should include assessment of plasma complement activity (eg, C5b-9), complement factor levels, renal tissue complement component staining (eg, C3, C4d), and complement-related gene sequencing. Such precise etiologic stratification is critical for distinguishing “hypertension-associated TMA” from “aHUS presenting with hypertension”, and directly informs the decision to initiate targeted complement therapy (eg, eculizumab). In the future, integrating detailed genetic and molecular data within larger prospective cohorts may enable faster differential diagnosis and more etiology-driven individualized treatment, ultimately improving patient outcomes. Renal Pathological Patterns Reveal Distinct Mechanisms of Injury Between RL-TMA and Sys-TMA Comparative renal pathological analysis demonstrated that systemic thrombotic microangiopathy (Sys-TMA) is predominantly characterized by acute microvascular injury, manifesting as marked glomerular endothelial cell swelling/proliferation and prominent acute vascular lesions. In contrast, RL-TMA patients showed more chronic changes on biopsy—glomerulosclerosis, arteriolar hyalinosis, and tubulointerstitial fibrosis. But we should be careful here: these changes may partly reflect the patients’ older age rather than the disease itself, since age is known to drive chronic vascular and glomerular remodeling. This pathological divergence aligns with the observed etiological distribution. Sys-TMA is often seen in patients with conditions that trigger rapid, widespread complement activation—autoimmune diseases and pregnancy, for example. This can lead to formation of the membrane attack complex (MAC) and direct endothelial injury.17,18 Conversely, RL-TMA is more commonly associated with chronic endothelial insults such as hypertension, and its pathological features are likely to reflect sustained, low-grade complement activation and chronic inflammation, which promote immune complex deposition and drive progressive fibrotic remodeling of the vascular wall.19–21 These findings are consistent with previous reports.9,22 Of particular significance, the RL-TMA group demonstrated prominent immunofluorescence findings in renal tissue, including higher global fluorescence intensity and significant deposition of IgG (especially IgG2/IgG4 subtypes) and C1q. This challenges the traditional view of hypertension-induced renal injury as purely “mechanical”, suggesting that immune mechanisms—particularly activation of the classical complement pathway—may play a crucial role.23 This observation aligns with recent perspectives proposing that some cases of “hypertension-associated TMA” may in fact represent an unrecognized, complement-mediated disease with predominant renal involvement (eg, primary atypical hemolytic uremic syndrome).6,24 Supporting this hypothesis is evidence that a substantial proportion of such patients carry pathogenic complement gene mutations,15,23 and that targeted complement therapy (eg, eculizumab) in these patients leads to significantly better renal outcomes compared with blood pressure control or plasma exchange alone.13 However, alternative explanations for the observed immune complex deposition must be carefully considered. First, chronic microvascular injury—such as that induced by long-standing hypertension—may increase vascular permeability, leading to nonspecific passive leakage of plasma proteins, including immunoglobulins and complement components, into the vessel wall, thereby producing immunofluorescence patterns that mimic immune-mediated deposition without necessarily reflecting active pathogenic immune processes. Second, as detailed in the Results section, RL-TMA patients frequently have coexisting immune complex-mediated glomerular diseases; in our cohort, IgA nephropathy, membranous nephropathy, and lupus nephritis collectively accounted for 40.5% of RL-TMA cases. In such patients, immune complex deposition may primarily reflect the underlying glomerular disease rather than a TMA-specific pathogenic mechanism. Nevertheless, the selective deposition patterns—particularly the predominance of IgG2/IgG4 subclasses and C1q—may still point toward classical complement pathway involvement in at least a subset of RL-TMA patients, raising the possibility that some cases currently classified as “hypertension-associated TMA” may actually represent unrecognized complement-mediated diseases with predominant renal involvement. Future studies employing more precise techniques, such as immunoelectron microscopy to determine the exact localization of immune deposits and their spatial relationship to endothelial injury, are needed to distinguish active pathogenic deposition from passive leakage and to clarify whether immune complex deposition in RL-TMA is a driver of disease or an epiphenomenon of chronic vascular damage. In summary, our pathological analysis not only supports the clinical distinction between the two groups but also reveals underlying mechanistic differences: based on these observations, we propose that Sys-TMA may represent an acute complement-driven process, whereas RL-TMA may constitute a renal-limited form of chronic immune-microvascular injury. This interpretation, however, remains hypothetical and requires direct testing in future studies. These findings provide important pathophysiological support for RL-TMA as a distinct clinical entity and strongly suggest that all RL-TMA patients—especially those with significant immune complex deposition—should undergo comprehensive evaluation of the complement system to identify individuals who may benefit from targeted therapy. Comparison of Clinical and Pathological Characteristics Between Dialysis and Non-Dialysis Patients with RL-TMA A comparison of clinical and pathological characteristics between dialysis-requiring and non-dialysis patients with RL-TMA revealed no significant differences in age, sex, body mass index, or blood pressure. However, the dialysis group exhibited a high-risk clinical–pathological profile associated with rapid disease progression. These patients presented with more severe renal dysfunction, a more pronounced inflammatory state (elevated C‑reactive protein), more severe anemia, and more prominent chronic glomerulosclerosis and tubular atrophy on pathological examination. We hypothesize that multiple factors exacerbate microvascular endothelial injury in RL-TMA, promoting glomerulosclerosis and interstitial fibrosis.8 These mechanisms may also suppress erythropoietin production, disrupt iron metabolism (contributing to anemia of chronic disease), and exacerbate malnutrition, collectively resulting in disproportionately severe anemia relative to the degree of renal dysfunction.25,26 Importantly, owing to the absence of typical systemic manifestations, diagnosis in such patients is often delayed, allowing this inflammation–fibrosis cascade to progress insidiously for years before clinical recognition27,28 and ultimately leading to irreversible kidney failure characterized by extensive chronic pathological damage. Association Between Clinicopathological Features and Renal Prognosis in Renal-Limited Thrombotic Microangiopathy (RL-TMA) In this study, we systematically evaluated—for the first time in a dedicated cohort—the associations between clinicopathological variables and renal outcomes in patients with renal-limited thrombotic microangiopathy (RL-TMA). Our univariate analysis showed that lower hemoglobin levels were linked to worse renal outcomes. Serum albumin did not show a significant association in our cohort. Although previous studies have indicated that RL-TMA is associated with a more favorable overall prognosis than systemic thrombotic microangiopathy5, refined prognostic assessment within this subgroup has remained limited. Our findings highlight a potential association between hemoglobin and renal outcomes that merits further investigation. Hemoglobin levels were associated with renal outcomes in our analysis. The reduction in hemoglobin levels is not merely a consequence of renal dysfunction but may also serve as a warning signal, suggesting underlying systemic abnormalities such as inflammation and malnutrition. Anemia in RL‑TMA differs from the acute microangiopathic hemolysis seen in systemic thrombotic microangiopathy and is more likely to be a multifactorial, chronic condition driven by the following mechanisms: (1) Chronic inflammation upregulates hepcidin, leading to functional iron deficiency and directly inhibiting erythropoietin (EPO) production and response;25,26 (2) TMA-associated microvascular endothelial damage may impair the peritubular microcirculation and interstitial fibroblasts early in the disease course, resulting in erythropoietin production failure and contributing to anemia that occurs earlier or is more severe than the decline in kidney function; and (3) Anemia is also associated with malnutrition and potential complement abnormalities. Therefore, anemia—especially when it presents early or is disproportionate to the degree of kidney dysfunction—may indicate a more active inflammatory state, more extensive microvascular injury, and a worse prognosis.22 Serum albumin did not show a clear association in this cohort. In addition, higher baseline serum creatinine and sodium levels were also associated with an increased risk of the composite renal endpoint in univariate analysis. The finding for creatinine is not unexpected, as it largely reflects baseline renal function. The association with sodium, however, is more difficult to interpret and may be a chance finding given the small sample size and wide confidence interval. These results should therefore be regarded as exploratory rather than definitive. Hemoglobin, as a readily obtainable parameter, may be helpful in identifying high-risk RL-TMA patients, but this potential utility requires further validation in larger prospective studies. However, given the small number of outcome events (n=4), these univariate findings should be interpreted with extreme caution and are considered hypothesis-generating rather than confirmatory. They do not establish hemoglobin, creatinine, or sodium as independent prognostic biomarkers. Multivariable analysis was not feasible, and these results require validation in larger prospective cohorts. Treatment and Prognostic Evaluation of Patients with RL-TMA and Sys-TMA The observed differences in treatment strategies and outcomes in this study provide important insights into the fundamentally distinct disease courses of renal-limited thrombotic microangiopathy (RL-TMA) and systemic thrombotic microangiopathy (Sys-TMA). Patients in the Sys-TMA group were more likely to receive intensive therapies such as plasma exchange and eculizumab, consistent with the clinical imperative to rapidly control an acute, systemic complement-mediated “storm”.29,30 Importantly, among patients requiring dialysis at baseline, the proportion achieving dialysis independence was significantly higher in the Sys-TMA group. This finding aligns with the predominance of acute, active lesions in this group and suggests that tissue injury driven by explosive complement activation may be partly reversible when timely and effective interventions are administered, indicating a distinct therapeutic window for renal recovery.31–35 In contrast, RL-TMA appeared to follow a more chronic, progressive course in our descriptive observation, although the difference in progression-free survival did not reach statistical significance The rate of dialysis withdrawal was very low, the survival curve exhibited a persistent gradual decline, and progression to end-stage renal disease was generally irreversible once established. These outcomes correlate closely with the prominent chronic and fibrotic pathological features observed in RL-TMA kidneys, such as glomerulosclerosis and interstitial fibrosis.4,22 Moreover, the marked immune complex deposition identified in this study further suggests that sustained low-grade immune activation may superimpose on chronic injury, collectively driving progressive microvascular remodeling. Thus, we propose that Sys-TMA may represent a clinical manifestation of acute complement activation, where the key to management lies in early detection and intervention during the acute phase. Conversely, RL-TMA could be conceptualized, as a working hypothesis, as a renal-limited form of thrombotic microangiopathy associated with chronic immune-microvascular injury, and its core risk lies in insidious, progressive fibrosis. These interpretations, however, remain speculative and require direct testing in future studies. This distinction offers a clear conceptual framework for clinical practice: for Sys-TMA, the focus is on rapid diagnosis and targeted treatment in the acute setting; for RL-TMA, the primary challenge is early identification and intervention to delay progression toward irreversible fibrotic outcomes. In summary, although our findings suggest complement may be involved in some RL-TMA patients, this interpretation is tempered by the fact that 40.5% of these patients had coexisting immune-complex glomerulonephritis. Whether the observed immune deposits are pathogenic or merely reflect chronic vascular leakage requires further study using immunoelectron microscopy and functional complement assays. Study Limitations This study has several limitations. First, the sample size was limited and imbalanced: the systemic thrombotic microangiopathy (Sys-TMA) group included only five patients, markedly fewer than the renal-limited thrombotic microangiopathy (RL-TMA) group (n = 42). This imbalance primarily reflects the critical condition of patients with systemic thrombotic microangiopathy and the low kidney biopsy rate in this population, and may have reduced the statistical power of intergroup comparisons and the reliability of the multivariable model. Second, the two groups differed substantially in age. RL-TMA patients were about 15 years older on average. This matters because age is closely linked to chronic vascular changes, arteriolar hyalinosis, glomerulosclerosis, and tubulointerstitial fibrosis—exactly the features we saw more of in the RL-TMA group. So we cannot rule out that these chronic changes reflect age-related kidney aging and vascular remodeling rather than something specific to RL-TMA. This should be kept in mind when interpreting the pathological differences, and our conclusions about chronic features as characteristic of RL-TMA need to be read with caution. Third, limitations inherent to the retrospective design should be noted. Missing follow-up data is possible, and diagnostic and therapeutic approaches for earlier cases may not have been optimal. Treatment regimens were not standardized and varied among individuals, particularly given the limited use of complement-targeted therapy, making it difficult to evaluate its true efficacy. Fourth, there were constraints in diagnostic and assessment methods. Some patients (especially those enrolled earlier) lacked systematic testing for complement activation markers (eg, C5b-9), factor levels, and genetic sequencing, which may have affected the accuracy of etiological classification. Specifically, not all patients underwent complete complement genetic analysis or comprehensive functional complement assays, and the availability of ADAMTS13 testing varied depending on clinical presentation and time of admission. This incomplete assessment may have led to underrecognition of complement-mediated cases, particularly in the RL-TMA group, and should be considered when interpreting the etiological distribution. Multivariate analysis was not performed due to the limited sample size, and therefore independent etiologic risk factors could not be assessed. Future prospective studies with standardized complement and genetic evaluation at baseline are needed to more precisely define the etiological spectrum of RL-TMA. Finally, the follow-up duration was relatively short. The median follow-up period was approximately 16–20 months, which is insufficient to capture long-term renal endpoints in a chronic, slowly progressive disease such as RL-TMA. Future prospective, multicenter studies with larger sample sizes, incorporating comprehensive complement–immunological assessments and extended follow-up, are needed to further validate and extend the findings of this study. In addition, emerging technologies such as large language models may offer novel opportunities for integrating complex clinicopathological data in TMA. However, such tools should be viewed as adjuncts to, rather than replacements for, comprehensive clinical evaluation.36 Conclusion In summary, this study—by systematically applying a semiquantitative pathological scoring system within a well-defined cohort—provides preliminary evidence clarifying the fundamental differences between renal-limited thrombotic microangiopathy (RL‑TMA) and systemic thrombotic microangiopathy (Sys‑TMA) in terms of clinical baseline characteristics, etiological spectrum, renal pathological damage patterns, and disease progression. These findings suggest that RL-TMA may represent a distinct clinicopathological entity and suggest that hemoglobin may be a potential marker worthy of further investigation for risk assessment in RL-TMA patients. Given the small sample size of the Sys-TMA group (n = 5) and the retrospective nature of this study, and the substantial age imbalance between the two groups, these results should be interpreted as exploratory and hypothesis-generating, and all findings require confirmation in larger prospective cohorts with standardized diagnostic evaluation and longer follow-up. Future research should focus on designing prospective, multicenter, large‑sample cohort studies that systematically integrate complement activation markers, genetic sequencing, and more refined molecular pathological assessments at the diagnostic stage. Such an approach would allow for more precise etiological subtyping of RL‑TMA and provide long‑term follow‑up data. This effort is essential for establishing optimal treatment strategies for different TMA subtypes, including RL‑TMA, particularly in defining the appropriate patient populations and intervention timing for complement inhibitors and other targeted therapies, ultimately aiming to improve patient outcomes. The present study provides an important preliminary foundation and direction for such in‑depth exploration. Funding Statement This study was supported by the following funding sources: The Anhui Provincial Key Research and Development Program - Population Health Special Project (Grant No. 202004j07020011); The Key Project of Natural Science Research for Universities in Anhui Province (Grant No. 2023AH051936); The Anhui Provincial Health Research Project (Grant No. AHWJ2024BAc30020); and a grant from the 2025 Action Plan for Cultivating Young and Middle-aged Faculty in Higher Education Institutions — Domestic Visiting Scholars Program for Young Key Teachers (Grant No. JNFX2025035). Data Sharing Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethics Approval and Consent to Participate This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Bengbu Medical college (Approval No. [2020]117). Informed consent was obtained from all individual participants included in the study. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The author(s) report no conflicts of interest in this work. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.